Cipla has become the latest in a line of generics firms to settle US patent litigation over Revlimid (lenalidomide) with Bristol Myers Squibb’s Celgene, gaining a date-certain launch for limited volumes of the multiple myeloma treatment followed by a later opportunity to launch an unlimited supply.
Noting that it will be able to market “volume-limited amounts of generic lenalidomide in the US beginning on a confidential...





